Clinical Trial Update: Safety and Efficacy Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial results for AA4500 (XIAFLEX) in advanced Dupuytren's disease demonstrated safety and efficacy, with results posted in October 2010.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dupuytren Disease

Drugs mentioned

• XIAFLEX (Collagenase Clostridium histolyticum)

Snippet

Sponsor: Endo Pharmaceuticals | Conditions: Advanced Dupuytren's Disease | Phase 3 | Status: COMPLETED | Results posted: 2010-10-22